Silvain, Christine

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 642

Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult‐to‐treat primary biliary cholangitis

Soret, P., Lam, L., Carrat, F., Smets, L., Berg, T., Carbone, M., Invernizzi, P., Leroy, V., Trivedi, P., Cazzagon, N., et al. (2021) · Alimentary Pharmacology & Therapeutics

Liver Diseases and ImmunityDrug Transport and Resistance Mechanisms

Cited by 78

A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)

Corpechot, C., Chazouillères, O., Rousseau, A., Guyader, D., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2017) · Journal of Hepatology

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 45

Why do liver transplant patients so often become obese? The addiction transfer hypothesis

Brunault, P., Salamé, E., Jaafari, N., Courtois, R., Réveillère, C., Silvain, C., Benyamina, A., Blecha, L., Belin, D., & Ballon, N. (2015) · Medical Hypotheses

Organ Transplantation Techniques and OutcomesAlcohol Consumption and Health Effects

Cited by 22